(GPCR) Structure Therapeutics - Ratings and Ratios
Obesity, Diabetes, Pulmonary Fibrosis, Small Molecule, GPCR
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 85.5% |
| Value at Risk 5%th | 108% |
| Relative Tail Risk | -23.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.33 |
| Alpha | 201.31 |
| CAGR/Max DD | 1.02 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.315 |
| Beta | 0.613 |
| Beta Downside | 1.352 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.96% |
| Mean DD | 41.80% |
| Median DD | 47.08% |
Description: GPCR Structure Therapeutics January 18, 2026
Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage biopharma focused on orally administered small-molecule therapeutics for chronic diseases with high unmet need in the U.S., leveraging biased agonism of G-protein-coupled receptors (GPCRs).
Its lead candidate, **GSBR-1290**, is a biased GLP-1 receptor agonist currently enrolled in two Phase 2 trials targeting obesity, overweight, and related metabolic conditions. A second oral molecule, **ACCG-2671**, remains in pre-clinical development for the same indication, while **ANPA-0073** (an apelin-receptor agonist) is “Phase 2-ready” for selective or muscle-sparing weight-loss studies. The company’s pipeline also includes **LTSE-2578**, an LPA1 antagonist aimed at idiopathic pulmonary fibrosis, and exploratory programs on GIPR and GCGR modulation.
Key sector metrics that shape Structure’s upside: the U.S. obesity drug market is projected to exceed **$30 billion by 2028**, driven by payer willingness to cover GLP-1 therapies; oral small-molecule GLP-1 agonists could capture a premium share if they demonstrate comparable efficacy with lower injection-related costs. Additionally, biotech cash burn averages **$150 M-$200 M per year** for companies at a similar stage, making runway length a critical KPI.
As of the latest filing, Structure reported **≈ $85 million in cash and equivalents**, giving it roughly **12-month** operating runway assuming current burn rates, and a **market-cap of ~$180 million**, implying a **price-to-cash ratio of ~2.1×**-a valuation metric often used to gauge liquidity risk in early-stage biotech.
For a deeper quantitative view, the ValueRay platform offers a data-driven analyst dashboard you may find useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -210.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA -12.42 > 1.0 |
| NWC/Revenue: 42.5k% < 20% (prev 66.9k%; Δ -24.5k% < -1%) |
| CFO/TA -0.23 > 3% & CFO -194.2m > Net Income -210.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.5m) vs 12m ago 2.24% < -2% |
| Gross Margin: 13.49% > 18% (prev -0.08%; Δ 1358 % > 0.5%) |
| Asset Turnover: 0.20% > 50% (prev 0.14%; Δ 0.06% > 0%) |
| Interest Coverage Ratio: -8.19 > 6 (EBITDA TTM -238.3m / Interest Expense TTM -29.2m) |
Altman Z'' -6.32
| A: 0.91 (Total Current Assets 814.0m - Total Current Liabilities 57.5m) / Total Assets 832.2m |
| B: -0.60 (Retained Earnings -503.3m / Total Assets 832.2m) |
| C: -0.27 (EBIT TTM -239.4m / Avg Total Assets 882.7m) |
| D: -8.09 (Book Value of Equity -502.5m / Total Liabilities 62.1m) |
| Altman-Z'' Score: -6.32 = D |
Beneish M
| DSRI: none (Receivables none/none, Revenue 1.78m/1.33m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 4.06 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 1.34 (Revenue 1.78m / 1.33m) |
| TATA: -0.02 (NI -210.7m - CFO -194.2m) / TA 832.2m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of GPCR shares?
Over the past week, the price has changed by -5.05%, over one month by +32.16%, over three months by +207.60% and over the past year by +210.17%.
Is GPCR a buy, sell or hold?
- StrongBuy: 8
- Buy: 6
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GPCR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 107.8 | 21.1% |
| Analysts Target Price | 107.8 | 21.1% |
| ValueRay Target Price | 88.9 | -0.2% |
GPCR Fundamental Data Overview January 24, 2026
Revenue TTM = 1.78m USD
EBIT TTM = -239.4m USD
EBITDA TTM = -238.3m USD
Long Term Debt = 7.09m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.80m USD (from shortTermDebt, last quarter)
Debt = 7.09m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -95.8m USD (from netDebt column, last quarter)
Enterprise Value = 5.70b USD (6.49b + Debt 7.09m - CCE 799.0m)
Interest Coverage Ratio = -8.19 (Ebit TTM -239.4m / Interest Expense TTM -29.2m)
EV/FCF = -29.01x (Enterprise Value 5.70b / FCF TTM -196.4m)
FCF Yield = -3.45% (FCF TTM -196.4m / Enterprise Value 5.70b)
FCF Margin = -11.0k% (FCF TTM -196.4m / Revenue TTM 1.78m)
Net Margin = -11.8k% (Net Income TTM -210.7m / Revenue TTM 1.78m)
Gross Margin = 13.49% ((Revenue TTM 1.78m - Cost of Revenue TTM 1.54m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 6.85 (Enterprise Value 5.70b / Total Assets 832.2m)
Interest Expense / Debt = 84.74% (Interest Expense 6.01m / Debt 7.09m)
Taxrate = 21.0% (US default 21%)
NOPAT = -189.1m (EBIT -239.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.15 (Total Current Assets 814.0m / Total Current Liabilities 57.5m)
Debt / Equity = 0.01 (Debt 7.09m / totalStockholderEquity, last quarter 770.0m)
Debt / EBITDA = 0.40 (negative EBITDA) (Net Debt -95.8m / EBITDA -238.3m)
Debt / FCF = 0.49 (negative FCF - burning cash) (Net Debt -95.8m / FCF TTM -196.4m)
Total Stockholder Equity = 807.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.87% (Net Income -210.7m / Total Assets 832.2m)
RoE = -26.08% (Net Income TTM -210.7m / Total Stockholder Equity 807.9m)
RoCE = -29.38% (EBIT -239.4m / Capital Employed (Equity 807.9m + L.T.Debt 7.09m))
RoIC = -23.41% (negative operating profit) (NOPAT -189.1m / Invested Capital 807.9m)
WACC = 8.16% (E(6.49b)/V(6.50b) * Re(8.17%) + (debt cost/tax rate unavailable))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.27%
Fair Price DCF = unknown (Cash Flow -196.4m)
EPS Correlation: -6.62 | EPS CAGR: 27.92% | SUE: -0.17 | # QB: 0
Revenue Correlation: 22.02 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.31 | Chg30d=+0.098 | Revisions Net=+2 | Analysts=7
EPS next Year (2026-12-31): EPS=-1.38 | Chg30d=+0.072 | Revisions Net=+5 | Growth EPS=-0.4% | Growth Revenue=+0.0%